iCardiac Technologies Inc has acquired the clinicial trials division of nSpire Health, according to an iCardiac news announcement.

iCardiac has opened an office in Longmont, Colo, to handle various business-related services as part of the deal, the company said. Terms of the deal, effective immedicately, were not disclosed.

“That working relationship confirmed for us that the people, solutions and technologies of nSpire are second to none,” said Alex Zapesochny, president and CEO of iCardiac. “It also made the decision to join forces with nSpire’s clinical trials division an easy one as iCardiac sought to expand our capabilities to better serve the growing demand for respiratory and inhaled therapeutics programs for asthma, COPD, cystic fibrosis and other indications.”